RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells

Journal of Biomedical Science

Volumn 22, Issue 1, 2015, Pages

  Dai, Chun Hua ^a   Li, Jian ^a   Chen, Ping ^a   Jiang, He Guo ^a   Wu, Ming ^b   Chen, Yong Chang ^b  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

Author keywords

Chemoresistance; Cisplatin; Core complex; Fanconi anemia BRCA pathway; Lung cancer; RNA interference

Indexed keywords

CISPLATIN; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA GROUP F PROTEIN; FANCONI ANEMIA GROUP L PROTEIN; FANCONI ANEMIA PROTEIN; SMALL INTERFERING RNA; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; FANCD2 PROTEIN, HUMAN; FANCF PROTEIN, HUMAN; FANCL PROTEIN, HUMAN;

A549 CELL LINE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG POTENTIATION; DRUG SENSITIVITY; FANCD2 GENE; FANCF GENE; FANCL GENE; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LUNG CANCER CELL LINE; PRIORITY JOURNAL; RNA INTERFERENCE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BRCA1 PROTEIN; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FANCONI ANEMIA COMPLEMENTATION GROUP F PROTEIN; FANCONI ANEMIA COMPLEMENTATION GROUP L PROTEIN; HUMANS; LUNG NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84941784640     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/s12929-015-0185-4     Document Type: Article

References (44)

1. Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs. Oncol Rep. 2004;11:559-95.
2. Chua YJ, Steer C, Yip D. Recent advances in management of small-cell lung cancer. Cancer Treat Rev. 2004;30:521-43.
3. Schiller JH, Harington D, Balani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002;346:92-8.
4. Li J, Dai C-H, Chen P, Wu J-N, Bao Q-L, Qiu H, et al. Survival and prognostic factors in small cell lung cancer. Med Oncol. 2010;27:73-81.
5. Jung Y, Lipapard SJ. Direct cellular response to platinum-induced DNA damage. Chem Rev. 2007;107:1387-407.
6. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4:307-20.
7. Ahmad S. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodivers. 2010;7:543-66.
8. Kim H, D'Andrea AD. Regulation of DNA cross-link repair by the fanconi anemia/BRCA pathway. Genes Develop. 2012;26:1393-408.
9. Li J, Li Z-N, Ou Y-J, Li X-Q, Bao Q-L, Chen P. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. Clin Lung Cancer. 2009;6:414-21.
10. Wang H, Zhang S-Y, Wang S, Lu J, Wu W, Weng L, et al. REV3 L confers chemoresistance to cisplatin in human gliomas: The potential of its RNAi for synergistic therapy. Neuro-Oncol. 2009;11:790-802.
11. Kee Y, D'Andrea AD. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 2010;24:1680-94.
12. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anemia and BRCA proteins. Nat Rev Genet. 2007;8:735-48.
13. Levran O, Attwooll C, Henry RT, Miton KL, Neveling K, Rio P, et al. The BRCA-interacting helicase BRIP1 is deficient in Fanconi anemia. Nature Genet. 2005;37:931-3.
14. Smogorzewska A, Matsuoka S, Vinciguerra P, Mc Donald ER, Hurov KE, Luo J, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell. 2007;129:289-301.
15. Kim Y, Lach FP, Desetty R, Hanenbery H, Auerbach AD, Smogorzewska A. Mutations of the SLX4 gene in Fanconi anemia. Nature Genet. 2011;43:142-6.
16. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nature Genet. 2010;42:406-9.
17. Bogliolo M, Schuster B, Stoepker C, Derkunt B, Su Y, Raams A, et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am J Hum Genet. 2013;92:800-6.
18. Garner E, Smogorzewska A. Ubiquitylation and the Fanconi anemia pathway. FEBS Lett. 2011;585:2853-60.
19. Knipscheer P, Raschle M, Smogorzewska A, Enoiu M, Ho TV, Scharer OD, et al. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science. 2009;326:1698-701.
20. Kottemann MC, Smogorzewska A. Fanconi anemia and the repair of Watson and Crick DNA crosslinks. Nature. 2013;493:356-63.
21. Gallmeier E, Calhoun ES, Rago C, Brody JR, Cunninghan SC, Hucl T, et al. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology. 2006;130:2145-54.
22. Van der Heijden MS, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA, Shen D, et al. Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol. 2004;165:651-7.
23. Huang Y, Leung JWC, Lowery M, Matsushita N, Wang Y, Shen X, et al. Modulatized functions of the Fanconi anemia core complex. Cell Rep. 2014;7:1-19.
24. Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood. 2006;107:4223-33.
25. Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman A-R, et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther. 2006;5:952-6.
26. Yu J, Zhao L, Li Y, Li N, He M, Bai X, et al. Silencing of Fanconi anemia complementation group F exhibits potent chemosenstization of mitomycin C activity in breast cancer cells. J Breast Cancer. 2013;16:291-9.
27. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood. 2005;106:698-705.
28. Plasencia C, Martinez-Balibrea E, Martinez-Cardus A, Quinn DI, Abad A, Neamati N. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT 29 colon cancer cells. Int J Oncol. 2006;29:225-35.
29. Huanq Z, Tong Y, Wang J, Huang Y. NMR studies of the relationship between the changes of membrane lipids and the cisplatin-resistance ofA549/DDP cells. Cancer Cell Int. 2003;8:5.
30. Tang X-P, Li J, Yu L-C, Chen Y-C, Shi S-B, Zhu L-R, et al. Clinical significance of survivin and VEGF mRNA detection in the cell fraction of the peripheral blood in non-small cell lung cancer patients before and after surgery. Lung Cancer. 2013;81:273-9.
31. -δδCt method. Methods. 2001;25:402-8.
32. Medhurst AL, Laghmani H, Steltenpool J, Ferrer M, Fontaine C, de Groot J, et al. Evidence for subcomplexes in the Fanconi anemia pathway. Blood. 2006;108:2072-80.
33. Ling C, Ishiai M, Ali AM, Medhurst AL, Neveling K, Kalb R, et al. FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. EMBO J. 2007;26:2104-14.
34. Leveille F, Blom E, Medhurst AL, Bier P, Lanhmani H, Johnson M, et al. The Fanconi anemia gene product FANCF is a flexible adaptor protein. J Biol Chem. 2004;279:39421-30.
35. Ali AM, Pradhan A, Singh TR, Du C, Li J, Wahengbam K, et al. FAAP 20: a novel ubiquitin-binding FA nuclear core-complex protein required for functional integrity of the FA-BRCA DNA repair pathway. Blood. 2012;119:3285-94.
36. Reuter T, Herterich S, Bernhard Q, Hoehn H, Gross HJ. Strong FANCA/FANCG but week FANCA/FANCC interaction in the yeast z-hybrid system. Blood. 2000;95:719-20.
37. Rajendra E, Oestergaard VH, Langevin F, Wang M, Dornan GL, Patel KJ, et al. The genetic and biochemical basis of FANCD2 monoubiquitination. Mol Cell. 2014;54:858-69.
38. Kowl P, Gurtan AM, Stuckert P, D'Andrea AD, Ellenberger T. Structural determinants of human FANCF protein that function in the assembly of a DNA damage signaling complex. J Biol Chem. 2007;282:2047-55.
39. Cole AR, Lewis LP, Walden H. The structure of the catalytic subunit FANCL of the Fanconi anemia core complex. Nat Struct Mol Biol. 2012;17:294-8.
40. Alpl AF, Pace PE, Babu MM, Patel KJ. Mechanistic insight into site-restricted monoubiguitination of FANCD2 by Ubezt, FANCL, and FANCI. Mol Cell. 2008;32:767-77.
41. Gatcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, et al. Interaction of Fanconi anemia proteins and BRCA1 in a common pathway. Mol cell. 2001;7:249-62.
42. Palle K, Vaziri C. Rad 18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA topoisomerase I inhibition. Cell Cycle. 2011;10:1625-38.
43. Song IY, Ralle K, Gurkar A, Tateishi S, Kupfer GM, Vaziri C. Rad 18-mediated translesion sythesis of bulky DNA adducts in coupled to activation of the Fanconi anemia DNA repair pathway. J Biol Chem. 2010;285:31525-36.
44. Wullner U, Neef I, Tur M, Bath S. Targeted delivery of short interfering RNAs-strategies for in vivo delivery. Recent Pat Anticancer Drug Discov. 2009;4:1-8.